Treatment selection bias for chemotherapy persists in colorectal cancer patient cohort studies even in comprehensive propensity score analyses

References

• van Leersum NJ, Janssen-Heijnen ML, Wouters MW, et al. Increasing prevalence of comorbidity in patients with colorectal cancer in the South of the Netherlands 1995–2010. Int J Cancer. 2013;132:2157–2163. doi:10.1002/ijc.2787123015513
   PubMed Web of Science ®Google Scholar
• Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi64–vi72. doi:10.1093/annonc/mdt35424078664
   PubMed Web of Science ®Google Scholar
• Pox C, Aretz S, Bischoff SC, et al. S3-Leitlinie Kolorektales Karzinom Version 1.0 – Juni 2013 AWMF-Registernummer: 021/007OL. Z Gastroenterol. 2013;51:753–854. doi:10.1055/s-0033-135026423955142
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22–iv40. doi:10.1093/annonc/mdx07528881920
   PubMed Web of Science ®Google Scholar
• Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21:1293–1300. doi:10.1200/JCO.2003.06.17812663717
   PubMed Web of Science ®Google Scholar
• Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S, Repelaer van Driel OJ, Coebergh JW. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg. 2005;92:615–623. doi:10.1002/bjs.491315779071
   PubMed Web of Science ®Google Scholar
• McGory ML, Zingmond DS, Sekeris E, Bastani R, Ko CY. A patient’s race/ethnicity does not explain the underuse of appropriate adjuvant therapy in colorectal cancer. Dis Colon Rectum. 2006;49:319–329. doi:10.1007/s10350-005-0283-616475031
   PubMed Web of Science ®Google Scholar
• Bradley CJ, Given CW, Dahman B, Fitzgerald TL. Adjuvant chemotherapy after resection in elderly Medicare and Medicaid patients with colon cancer. Arch Intern Med. 2008;168:521–529. doi:10.1001/archinternmed.2007.8218332299
   PubMedGoogle Scholar
• Sarfati D, Hill S, Blakely T, et al. The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study. BMC Cancer. 2009;9:116. doi:10.1186/1471-2407-9-11619379520
   PubMed Web of Science ®Google Scholar
• Chagpar R, Xing Y, Chiang YJ, et al. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol. 2012;30:972–979. doi:10.1200/JCO.2011.39.693722355049
   PubMed Web of Science ®Google Scholar
• Chandhoke G, Wei XJ, Nanji S, et al. Patterns of referral for adjuvant chemotherapy for stage II and III colon cancer: a population-based study. Ann Surg Oncol. 2016;23:2529–2538. doi:10.1245/s10434-016-5181-826965700
   PubMed Web of Science ®Google Scholar
• Hsieh MC, Thompson T, Wu XC, et al. The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients. Cancer Med. 2016;5:871–880. doi:10.1002/cam4.63226773804
   PubMed Web of Science ®Google Scholar
• Murphy CC, Harlan LC, Lund JL, Lynch CF, Geiger AM. Patterns of colorectal cancer care in the United States: 1990–2010. J Natl Cancer Inst. 2015;107:djv198.26206950
   PubMedGoogle Scholar
• Hu CY, Delclos GL, Chan W, Du XL. Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer. Med Oncol. 2011;28:1062–1074. doi:10.1007/s12032-010-9644-720714945
   PubMed Web of Science ®Google Scholar
• Gustavsson B, Carlsson G, Machover D, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015;14:1–10. doi:10.1016/j.clcc.2014.11.00225579803
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091–1097. doi:10.1056/NEJMoa01095711596588
   PubMed Web of Science ®Google Scholar
• Booth CM, Nanji S, Wei X, et al. Use and effectiveness of adjuvant chemotherapy for stage III colon cancer: a population-based study. J Natl Compr Canc Netw. 2016;14:47–56.26733554
   PubMed Web of Science ®Google Scholar
• Hines RB, Bimali M, Johnson AM, Bayakly AR, Collins TC. Prevalence and survival benefit of adjuvant chemotherapy in stage III colon cancer patients: Comparison of overall and age-stratified results by multivariable modeling and propensity score methodology in a population-based cohort. Cancer Epidemiol. 2016;44:77–83. doi:10.1016/j.canep.2016.08.00427513721
   PubMed Web of Science ®Google Scholar
• Sanoff HK, Carpenter WR, Stürmer T, et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 2012;30:2624–2634. doi:10.1200/JCO.2011.41.114022665536
   PubMed Web of Science ®Google Scholar
• Zuckerman IH, Rapp T, Onukwugha E, et al. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer. J Am Geriatr Soc. 2009;57:1403–1410. doi:10.1111/j.1532-5415.2009.02355.x19563521
   PubMed Web of Science ®Google Scholar
• Boland GM, Chang GJ, Haynes AB, et al. Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer. 2013;119:1593–1601. doi:10.1002/cncr.2793523280510
   PubMed Web of Science ®Google Scholar
• Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol. 2002;20:3992–3998. doi:10.1200/JCO.2002.03.08312351596
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399–424. doi:10.1080/00273171.2011.56878621818162
   PubMed Web of Science ®Google Scholar
• Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, Hoffmeister M. Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology. 2014;146:709–717. doi:10.1053/j.gastro.2013.09.00124012982
   PubMed Web of Science ®Google Scholar
• Hoffmeister M, Jansen L, Rudolph A, et al. Statin use and survival after colorectal cancer: the importance of comprehensive confounder adjustment. J Natl Cancer Inst. 2015;107:djv045. doi:10.1093/jnci/djv04525770147
   PubMedGoogle Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.3558716
   PubMedGoogle Scholar
• Owens WD, Felts JA, Spitznagel EL Jr. ASA physical status classifications: a study of consistency of ratings. Anesthesiology. 1978;49:239–243. doi:10.1097/00000542-197810000-00003697077
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.7165009
   PubMed Web of Science ®Google Scholar
• Karnofsky DA, Abelmann WH, Craver LF, et al. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer. 1948;1:634–656. doi:10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L
   Web of Science ®Google Scholar
• European Society for Medical Oncology [homepage on the Internet]. Performance scales: Karnofsky & ECOG scores. 2018 Available from: https://oncologypro.esmo.org/Oncology-in-Practice/Practice-Tools/Performance-Scales/. Accessed 83, 2018.
   Google Scholar
• Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661–3679. doi:10.1002/sim.660726238958
   PubMed Web of Science ®Google Scholar
• Lee BK, Lessler J, Stuart EA. Weight trimming and propensity score weighting. PLoS One. 2011;6:e18174. doi:10.1371/journal.pone.001817421483818
   PubMed Web of Science ®Google Scholar
• Mantel N, Byar DP. Evaluation of response-time data involving transient states: an illustration using Heart-Transplant Data. J Am Stats Assoc. 1974;69:81–86. doi:10.1080/01621459.1974.10480131
   Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509. doi:10.1080/01621459.1999.10474144
   Web of Science ®Google Scholar
• McCarthy K, Pearson K, Fulton R, Hewitt J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev. 2012;12:Cd008368.23235660
   PubMed Web of Science ®Google Scholar
• Esnaola NF, Stewart AK, Feig BW, Skibber JM, Rodriguez-Bigas MA. Age-, race-, and ethnicity-related differences in the treatment of nonmetastatic rectal cancer: a patterns of care study from the national cancer data base. Ann Surg Oncol. 2008;15:3036–3047. doi:10.1245/s10434-008-0106-918712449
   PubMed Web of Science ®Google Scholar
• Boakye D, Rillmann B, Walter V, Jansen L, Hoffmeister M, Brenner H. Impact of comorbidity and frailty on prognosis in colorectal cancer patients: A systematic review and meta-analysis. Cancer Treat Rev. 2018;64:30–39. doi:10.1016/j.ctrv.2018.02.00329459248
   PubMed Web of Science ®Google Scholar
• Freemantle N, Marston L, Walters K, Wood J, Reynolds MR, Petersen I. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ. 2013;347:f6409. doi:10.1136/bmj.f640924217206
   PubMed Web of Science ®Google Scholar